  | |
TechnologyOverviewSea Run's platform technology is therapeutics from salmon plasma proteins. These proteins, primarily fibrinogen and thrombin, are safe and effective, and could transform the way that acute pain, bleeding, and neural injuries are treated. Salmon blood clots rapidly, and salmon can regenerate their spinal cord. Sea Run has found that these capabilities result in part from the coagulation proteins fibrinogen and thrombin (fibrin). These proteins are similar enough to human fibrinogen and thrombin to be interchangeable in terms of polymerization, but differ slightly in amino acid sequence and glycosylation, resulting in unique properties. An obvious concern with salmon fibrin is an immune response in the patient. Therefore, Sea Run has sponsored numerous animal trials, all with the same result. Salmon proteins induce antibodies, but these antibodies do not cross-react with the host animal's protein, and there have been no adverse symptoms in recipient animals. Furthermore, other salmon proteins such as salmon calcitonin and protamine have a long and useful clinical history. Worldwide production of farmed salmon now exceeds a million metric tons annually. Therefore, millions of liters of blood with consistent quality are available from animals where genetics, nutrition, and environment are controlled or closely monitored. |
SolutionsOur current focus is on SEA-STAT® TH which shows significant and sustained pain relief when applied after neural or soft tissue injury. (Weisshaar et al. 2010). This efficacy in pain reduction provides an alternative to opioids and their host of associated problems. However, we have identified numerous other applications where in animal trials, salmon fibrin provides unique benefits.
|